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Protective effect of rosiglitazone 
on kidney function in high-fat 
challenged human-CRP transgenic 
mice: a possible role for adiponectin 
and miR-21?
Martine C. Morrison  1, Gopala K. Yakala2, Wen Liang1, Peter Y. Wielinga1, Kanita Salic1, 
Arianne van Koppen1, Tushar Tomar  2, Robert Kleemann1, Peter Heeringa  2 & Teake 
Kooistra1
Obesity-related albuminuria is associated with decline of kidney function and is considered a first sign 
of diabetic nephropathy. Suggested factors linking obesity to kidney dysfunction include low-grade 
inflammation, insulin resistance and adipokine dysregulation. Here, we investigated the effects of 
two pharmacological compounds with established anti-inflammatory properties, rosiglitazone and 
rosuvastatin, on kidney dysfunction during high-fat diet (HFD)-induced obesity. For this, human CRP 
transgenic mice were fed standard chow, a lard-based HFD, HFD+rosuvastatin or HFD+rosiglitazone 
for 42 weeks to study effects on insulin resistance; plasma inflammatory markers and adipokines; and 
renal pathology. Rosiglitazone but not rosuvastatin prevented HFD-induced albuminuria and renal 
fibrosis and inflammation. Also, rosiglitazone prevented HFD-induced KIM-1 expression, while levels 
were doubled with rosuvastatin. This was mirrored by miR-21 expression, which plays a role in fibrosis 
and is associated with renal dysfunction. Plasma insulin did not correlate with albuminuria. Only 
rosiglitazone increased circulating adiponectin concentrations. In all, HFD-induced albuminuria, and 
renal inflammation, injury and fibrosis is prevented by rosiglitazone but not by rosuvastatin. These 
beneficial effects of rosiglitazone are linked to lowered miR-21 expression but not connected with the 
selectively enhanced plasma adiponectin levels observed in rosiglitazone-treated animals.
Obesity rates are rapidly rising worldwide in almost all populations and age groups, largely due to increased avail-
ability and consumption of calorie-dense foods with a high-fat, high-sugar content and lack of physical activity1. 
Obesity-related fat accumulation, especially in visceral depots, is associated with an increased risk of a number of 
pathologies, including insulin resistance (IR)2 and (micro) albuminuria3. Albuminuria has been associated with a 
decline of kidney function and is now being recognised not only as an important risk factor for future cardiovas-
cular events4, 5, but is also considered a first sign of diabetic nephropathy6. With the recent rise in the prevalence 
of obesity, there is an urgent need for a better understanding of why a relationship exists between obesity and 
albuminuria and how obesity-related albuminuria develops. Suggested factors linking obesity to albuminuria 
include systemic chronic low-grade inflammation, IR, and specific adipocyte-derived adipokines.
Chronic low-grade inflammation, as evidenced by elevated plasma levels of acute-phase inflammatory mark-
ers, including C-reactive protein (CRP), a commonly used marker for systemic inflammation in humans7, is 
thought to play an important role in the development of both IR and nephropathy. To show a causative relation-
ship between these risk markers and kidney disease, an intervention directed at reduction of systemic inflam-
mation should in turn at least partly diminish IR and prevent albuminuria. If that were true, interventions that 
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reduce systemic inflammation and insulin are attractive candidates for preventive treatment of patients at risk for 
developing (diabetic) nephropathy.
Another explanation for renal disease in obesity may be related to the notion that adipocytes are an active 
endocrine cell type8, 9. Adipocytes secrete several bioactive factors (adipokines) that reportedly play a role in 
maintaining metabolic health (reviewed in ref. 8). Obesity frequently leads to a dysregulation of adipokine secre-
tion from fat depots8 and thus may be associated with metabolic diseases. Of the numerous factors that are regu-
lated with increased visceral obesity, one of the best characterised is adiponectin. Recent clinical studies suggest 
that lowered plasma levels of adiponectin may play a key role in the development of obesity-related albuminuria10. 
Adiponectin is thought to regulate the function of podocytes, a renal cell-type that plays a significant role in the 
glomerular filtration barrier11. Indeed, studies in adiponectin knockout mice indicate that absence of adiponectin 
can contribute to the initial development of albuminuria10. Further evidence for beneficial effects of adiponectin 
on kidney functioning was sought by increasing plasma levels by administration of exogenous adiponectin, but 
these efforts were hampered by inherent difficulties in producing functional recombinant adiponectin, combined 
with the brief circulating half-life of adiponectin12. Therefore, efforts to increase adiponectin levels have also been 
focused on increasing the production of endogenous adiponectin by adipose tissue. Since the human and mouse 
adiponectin promoter contains binding sites for peroxisome proliferator-activated receptor gamma (PPAR-γ), 
pharmacological activation of PPAR-γ offers the opportunity to enhance endogenous plasma levels of adiponec-
tin and thereby to further substantiate a protective role of adiponectin in the development of kidney disease.
To gain more insight into the role of inflammation and adiponectin in metabolic-stress-induced albuminuria, 
renal inflammation and fibrosis in the context of IR, we used a human CRP transgenic (huCRPtg) mouse model. 
The huCRPtg mouse carries a transgene containing the human CRP gene, the 5′ flanking promoter region and 
all known human CRP gene regulatory elements13. These mice have been successfully employed to monitor sys-
temic inflammation and to determine the effects and mechanisms of drugs like statins and fibrates in reducing 
inflammatory process14. In a recent study15, we demonstrated that by feeding a high-fat diet (HFD), huCRPtg 
mice showed metabolic-stress-induced systemic inflammation and developed osteoarthritis. Interventions with 
a statin (rosuvastatin) and a PPAR-γ activator (rosiglitazone) reduced systemic inflammation as indicated by 
decreased human CRP levels and concomitantly inhibited the development of osteoarthritis. Here we have used 
this mouse model to evaluate whether suppression of HFD-induced systemic inflammation by rosuvastatin and 
rosiglitazone also improves albuminuria, renal inflammation and fibrosis under conditions of obesity and IR. An 
integral part of the study was to assess a putative role of adiponectin, which is induced by rosiglitazone.
Results
Body weight and fat distribution. HuCRPtg mice were fed a standard chow diet, a lard-based HFD, 
HFD+0.005% rosuvastatin or HFD+0.018% rosiglitazone for 42 weeks to study effects on insulin resistance, 
plasma inflammatory markers and adipokines, and renal pathology (albuminuria, inflammation and fibrosis). 
Body weight at baseline (t = 0) was 28.5 ± 2.1 g. The three experimental groups that received HFD all showed a 
gradual increase in body weight over time and all had significantly higher average body weights at the end of the 
experimental period (t = 42 weeks) compared with the group that remained on chow (35.1 ± 1.9 g). Mice treated 
with rosiglitazone had the highest body weight (57.7 ± 11.0 g), which was significantly higher than that of the 
HFD group (41.1 ± 4.7 g) and the rosuvastatin-treated group (46.1 ± 6.2 g)15.
All mice fed HFD showed a clear increase in fat mass compared with chow-fed mice, but what was most 
striking were the observed differences in fat mass distribution over the various fat depots in the different groups 
(Fig. 1a–c). Rosiglitazone treatment resulted in a reduction in visceral fat mass and an increase in subcutaneous 
fat mass in comparison with the HFD group (visceral fat: 0.39 ± 0.17 g vs. 0.65 ± 0.29 g, p < 0.01; subcutane-
ous fat: 2.93 ± 1.30 g vs. 0.83 ± 0.41 g, p < 0.001). In the rosuvastatin group, an increase in epididymal fat mass 
was observed in comparison with both the HFD group (HFD+Rosuva vs. HFD, 2.02 ± 0.95 g vs. 1.54 ± 0.32 g, 
p = 0.07) and the rosiglitazone group (HFD+Rosuva vs. HFD+Rosi, 2.02 ± 0.95 g vs. 1.27 ± 0.28 g, p < 0.01).
Figure 1. Effects of rosuvastatin and rosiglitazone on fat distribution. HuCRPtg mice were fed chow, high-fat 
diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) rosiglitazone (HFD Rosi) 
for 42 weeks. (a) Visceral fat mass, (b) subcutaneous fat mass, (c) epididymal fat mass. Data are mean ± SD. 
**p < 0.01, ***p < 0.001.
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Glucose and insulin levels. Plasma glucose levels were 9.8 ± 1.21 mM at the start of the experiment and 
increased steadily and significantly during the rest of the investigational period for all experimental groups: 
13.6 ± 1.8 mM (chow), 15.9 ± 2.5 mM (HFD), 14.8 ± 2.1 mM (HFD+Rosuva), and 14.2 ± 2.1 mM (HFD+Rosi) 
at t = 42 (Fig. 2a). Compared with glucose levels, changes in insulin levels over time were more pronounced and 
differed between groups. Average insulin levels were 0.6 ± 0.3 ng/ml at t = 0 and rose over time to 3.4 ± 1.7 ng/
ml at t = 42 weeks for the chow group and to 4.1 ± 0.6 ng/ml in HFD. Notably, the highest insulin levels were 
observed with rosuvastatin treatment (4.7 ± 1.0 ng/ml), whereas rosiglitazone treatment markedly and signifi-
cantly suppressed insulin levels to 2.3 ± 1.6 ng/ml (p < 0.05 compared with HFD) (Fig. 2b).
Plasma adipokines. Leptin is an adipokine that is highly specific for adipose tissue. Several studies of obese 
humans have shown a strong and consistent positive relation between plasma leptin concentrations and adi-
pose tissue mass (see ref. 16 and references therein). At the start of the experiment, plasma leptin levels were 
low (0.15 ± 0.3 ng/ml) and they increased slightly over time in the chow group (4.7 ± 2.2 ng/ml at t = 42 weeks) 
(Fig. 3a). After starting the HFD, leptin levels gradually and strongly rose in all three HFD groups (Fig. 3a). At 
t = 42 weeks, leptin levels in the rosiglitazone group had reached values of 35.9 ± 19.5 ng/ml, higher than those of 
the rosuvastatin group (30.1 ± 11.2 ng/ml) and the HFD group (21.8 ± 10.9 ng/ml, p < 0.05). Correlation analysis 
revealed a strong positive relationship between body mass and leptin levels (R2 = 0.8208, p < 0.0001, Fig. 3b), 
in line with the reported correlation between plasma leptin levels and adipose mass in humans16. In contrast 
to leptin, adiponectin levels are usually reduced with increasing obesity and associated comorbidities, such as 
type-2 diabetes (T2D)17. Grosso modo, adiponectin levels remained relatively constant in all treatment groups 
during the entire experimental period (t = 0: 7.4 ± 2.5 µg/ml; and t = 42: 9.4 ± 3.3 µg/ml in chow, 11.9 ± 1.2 µg/
ml in HFD, and 10.9 ± 2.8 µg/ml in HFD+Rosuva), except for the rosiglitazone group, which showed strongly 
increased plasma concentrations of adiponectin from t = 4 weeks onward, reaching average levels of 40.8 ± 9.9 µg/
ml (p < 0.001 compared with all other groups at t = 42, Fig. 3c).
Renal inflammation and renal function. At the end of the experimental period, the chow group had 
a urinary albumin/creatinine ratio of 151 ± 57 µg/mg. Both the HFD group (396 ± 232 µg/mg, p < 0.01) and 
the Rosuva group (361 ± 232 µg/mg, p < 0.05) showed a comparable and significant increase in the albumin/
creatinine ratio compared with the chow group (Fig. 4a). In contrast, HFD-fed mice treated with rosiglitazone 
exhibited urinary albumin/creatinine ratios of 129 ± 20 µg/mg, i.e. similar to those of chow-fed mice, and well 
below the values seen for the HFD and Rosuva groups (p < 0.01 compared with HFD, p < 0.05 compared with 
HFD+Rosuva; Fig. 4a). Notably, urinary albumin levels were not significantly correlated with plasma insulin 
levels (not shown).
Bright-field microscopy analysis revealed that HFD feeding induced development of mild mesangial area 
expansion and accumulation of lipid droplets in tubuli (Fig. 4b). Both rosuvastatin and rosiglitazone prevented 
mesangial expansion. Tubular lipid accumulation was also observed in the rosiglitazone-treated group, but was 
absent in the rosuvastatin-treated mice.
Gene expression analysis revealed that relative mRNA expression levels (expressed as fold-change relative to 
chow) of kidney injury molecule 1 (KIM-1) were markedly upregulated in HFD (2.15 ± 0.84, p = 0.08 vs. chow, 
Table 1). Notably, rosuvastatin markedly and significantly further increased KIM-1 expression levels (3.56 ± 2.18, 
p < 0.05 vs. HFD), whereas rosiglitazone kept KIM-1 mRNA levels as low as those found for the chow group, i.e. 
strikingly below values seen for the HFD and HFD+Rosuva groups. Immunofluorescence staining of KIM-1 
Figure 2. Effects of rosuvastatin and rosiglitazone on plasma glucose and insulin. HuCRPtg mice were 
fed chow, high-fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) 
rosiglitazone (HFD Rosi) for 42 weeks. (a) Plasma glucose levels, (b) plasma insulin levels. Data are mean ± SD. 
*p < 0.05, **p < 0.01.
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confirmed mild HFD-induced damage around tubular cells, showing a limited number of positively stained 
tubuli, which was absent in chow controls (not shown).
A similar pattern emerged with respect to the renal mRNA expression levels of the endothelial activation 
marker E-selectin (Table 1). HFD feeding significantly upregulated E-selectin mRNA expression (2.41 ± 0.73, 
p < 0.001 vs. chow), and rosuvastatin was unable to prevent this increase (2.23 ± 0.85, n.s. vs. HFD). In contrast, 
Figure 3. Effects of rosuvastatin and rosiglitazone on plasma leptin and adiponectin levels. HuCRPtg mice 
were fed chow, high-fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) 
rosiglitazone (HFD Rosi) for 42 weeks. (a) Plasma leptin levels over time. (b) Correlation between plasma leptin 
and body weight. (c) Plasma adiponectin levels over time. Data are mean ± SD.
www.nature.com/scientificreports/
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rosiglitazone treatment considerably downregulated E-selectin mRNA expression (1.38 ± 0.54, p < 0.01 vs. HFD), 
with expression levels similar to those observed in chow-fed mice.
The expression of CD68 mRNA, a marker for macrophage infiltration, and VCAM-1 mRNA, a vascular 
endothelial activation marker, did not differ significantly between the experimental groups (Table 1).
Plasma markers of systemic inflammation. HuCRP levels were measured to monitor the overall sys-
temic inflammatory state induced by HFD, and the effect of interventions with rosuvastatin and rosiglitazone 
thereupon. As reported previously, plasma huCRP levels were increased by HFD feeding and this induction was 
significantly quenched in animals treated with rosiglitazone or rosuvastatin15, as is also reflected by the signifi-
cant reduction in huCRP exposure during HFD-feeding (Fig. 5a). In contrast, only rosiglitazone markedly and 
significantly reduced the HFD-induced increase in plasma E-selectin levels at 42 weeks thus reflecting the renal 
mRNA data for E-selectin (Fig. 5b).
Renal fibrosis and miR-21. Renal fibrosis is a frequent underlying cause of decreased renal function. To 
gain insight into fibrosis development, kidneys were stained with Masson Trichrome and Picro-Sirius Red, and 
analyzed for collagen deposition. Figure 6a shows Masson’s Trichrome staining with the corresponding collagen 
quantification (as quantified in Picro-Sirius Red-stained sections) in Fig. 6b. HFD induced the tubular interstitial 
collagen content (1.11 ± 0.44%) compared with the chow group (0.57 ± 0.31%; p < 0.01, Fig. 6b). Notably, while 
collagen content after rosuvastatin treatment was comparable to that in the HFD group (1.27 ± 0.45%), rosiglita-
zone significantly prevented collagen deposition (0.74 ± 0.24%; p < 0.05 compared with HFD) with levels com-
parable to those in the chow group.
Since miR-21 has been shown to play a pathological role in many forms of fibrosis and since its increase is 
associated with microalbuminuria, inflammation and renal fibrosis18, 19, we examined renal miR-21 expression 
(Fig. 6c). Renal miR-21 expression was enhanced in HFD compared with chow group (fold-change 1.66 ± 0.83 
in HFD vs., 1.00 ± 0.42 in chow). Rosuvastatin treatment nearly doubled miR-21 expression (fold-change 
3.16 ± 1.41 relative to chow; p < 0.01 compared with HFD) on top of HFD treatment. In contrast, rosiglitazone 
kept miR-21 levels low (fold-change 1.32 ± 1.02 relative to chow). To test whether miR-21 expression is connected 
to kidney pathology, we performed correlation analyses. Renal miR-21 expression correlated significantly with 
renal KIM-1 expression (Spearman r = 0.46, p = 0.02) and renal fibrosis (Spearman r = 0.52, p = 0.003) while no 
such correlations were found for plasma adiponectin levels or adiponectin exposure.
Figure 4. Effects of rosuvastatin and rosiglitazone on urinary albumin and kidney histology. HuCRPtg mice 
were fed chow, high-fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) 
rosiglitazone (HFD Rosi) for 42 weeks. (a) Urinary albumin levels. (b) Representative photomicrographs of 
PAS-stained kidney sections showing mesangial expansion (open arrows) and lipid droplets in tubuli (filled 
arrows). Data are mean ± SD., *p < 0.05, **p < 0.01.
Chow HFD HFD+Rosuva HFD+Rosi
KIM-1 1.00 ± 0.25a 2.15 ± 0.84ac 3.56 ± 2.18b 1.22 ± 0.55ac
E-selectin 1.00 ± 0.33a 2.41 ± 0.73b 2.23 ± 0.85b 1.38 ± 0.54a
CD68 1.00 ± 0.13a 1.20 ± 0.33ab 1.31 ± 0.23b 1.41 ± 0.34b
VCAM-1 1.00 ± 0.22a 0.83 ± 0.31a 1.11 ± 0.38a 0.94 ± 0.27a
Table 1. Effects of rosiglitazone and rosuvastatin on renal mRNA expression. Fold-change relative to chow. 
Data are mean ± SD. Means in a row with superscripts that do not share a common letter differ significantly 
(p < 0.05).
www.nature.com/scientificreports/
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Discussion
Obesity-related albuminuria is recognised as a first sign of declined kidney function. Among the factors sug-
gested to connect obesity to kidney dysfunction are low-grade systemic inflammation, IR/T2D and adipokine 
dysregulation. In the current study we sought evidence for the role of these obesity-linked factors in the develop-
ment of aspects of renal pathology, viz. albuminuria, inflammation and fibrosis. For this, we employed huCRPtg 
mice under conditions of HFD-induced obesity in conjunction with two pharmacological interventions, rosigl-
itazone and rosuvastatin, with established anti-inflammatory properties15, as exemplified by decreased huCRP 
levels. Our results demonstrate that anti-inflammatory rosiglitazone but not anti-inflammatory rosuvastatin pre-
vented HFD-induced albuminuria and renal fibrosis, and inhibited expression of the renal inflammation marker, 
E-selectin. Rosiglitazone also prevented the HFD-enhanced mRNA expression of KIM-1, while rosuvastatin 
almost doubled KIM-1 mRNA levels. Notably, these beneficial effects of rosiglitazone were paralleled by absence 
of miR-21 induction, the expression of which was found to be correlated with kidney pathology (i.e. KIM-1 
expression and kidney fibrosis).
In our study, we focused on human CRP levels as a marker for systemic inflammation. Recently, it has 
been reported that rosiglitazone treatment reduces plasma CRP levels in rats with streptozotocin-induced 
T2D20. Consistent with these findings, we observed that rosiglitazone treatment reduced human CRP levels in 
HFD-challenged huCRPtg mice indicating that rosiglitazone suppresses systemic inflammatory responses15. 
Rosiglitazone is a PPAR-γ agonist that belongs to the thiazolidinedione class of drugs. It has been reported that in 
patients with T2D, treatment with another thiazolidinedione (pioglitazone) along with insulin therapy decreased 
human CRP levels when compared to insulin treatment alone21, 22. In the current study, rosiglitazone reduced 
plasma insulin levels and hence reduced IR. In contrast, anti-inflammatory rosuvastatin treatment15 failed to 
reduce circulating insulin levels, which is in line with a recent study showing that rosuvastatin failed to improve 
IR in patients on peritoneal dialysis23.
Rosiglitazone treatment caused a significant increase in body weight in huCRPtg mice compared with HFD 
mice. More specifically, rosiglitazone-treated mice especially had increased subcutaneous fat mass compared with 
HFD mice. Consistent with these observations, treatment with PPAR-γ agonists has been shown to improve insu-
lin sensitivity despite increasing body fat mass, in particular subcutaneously21. In contrast, an increase in visceral 
fat has been reported to be highly associated with IR and T2D22, 23. Here, we observed that rosiglitazone treatment 
decreased visceral fat mass. In contrast, in rosuvastatin-treated mice the mass and distribution of the fat depots 
were similar to those observed in untreated HFD-challenged mice.
We also observed that mice treated with rosiglitazone displayed markedly increased plasma levels of adi-
ponectin, a protein predominantly secreted by adipocytes. It is well documented that adiponectin is a cardiopro-
tective adipokine, due to its anti-inflammatory and insulin-sensitizing properties24, 25. An inverse relationship 
between adiponectin levels and CVD has been reported15, 26 in patients with end-stage renal disease, and there is 
increasing evidence that adiponectin plays a protective role in T2D and IR. For example, adiponectin-deficient 
mice are prone to develop IR and vascular damage after HFD challenge27 whereas treatment with adiponectin 
inhibits renal fibrosis and albuminuria in adiponectin knock-out mice24. Moreover, enhanced expression of adi-
ponectin attenuates inflammation and diabetes development in db/db mice28. Since plasma levels of adiponectin 
and adiponectin exposure over time did not correlate with kidney disease severity (percentage of fibrosis and 
KIM-1 expression) in the present study it is unlikely that adiponectin plays a causal role under the experimental 
conditions applied herein.
Figure 5. Effects of rosuvastatin and rosiglitazone on plasma huCRP and E-selectin. HuCRPtg mice were 
fed chow, high-fat diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) 
rosiglitazone (HFD Rosi) for 42 weeks. (a) huCRP exposure during HFD-feeding (b) plasma E-selectin at t = 42 
weeks. Data are mean ± SD. **p < 0.01, ***p < 0.001.
www.nature.com/scientificreports/
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Obesity-related albuminuria is now being recognised not only as an indication of declined kidney function 
and a first sign of diabetic nephropathy10, but also increases the risk of CVD29. If left untreated, patients with albu-
minuria are more prone to CVD. Treatments that reduce albuminuria are therefore inherently renoprotective and 
would improve CVD outcomes29. We observed that mice on HFD developed mesangial expansion, lipid accu-
mulation and albuminuria. Furthermore, KIM-1, a marker of kidney injury30, was upregulated in mice on HFD. 
Rosiglitazone treatment markedly diminished these HFD-induced renal effects and improved kidney function as 
evidenced by reduced urinary albumin/creatinine ratios and lowered KIM-1 expression. Moreover, rosiglitazone 
treatment strikingly reduced plasma E-selectin levels and, similarly, reduced renal E-selectin mRNA expression 
levels. Conversely, rosuvastatin treatment failed to exert any beneficial effects on markers of endothelial activation 
and inflammation in the kidney and did not improve albumin/creatinine ratios. In fact, the expression levels of 
some markers, including E-selectin and KIM-1 were increased in the kidneys of rosuvastatin-treated mice when 
compared with those of chow and HFD-challenged mice.
In a healthy individual, the kidney is able to reabsorb the majority of protein that enters the renal filtrate, with 
only traces being excreted in the urine. In the obese state there are two main sites involving two different pro-
cesses that result in a loss of protein (mainly albumin) in the urine, viz. (i) structural changes to the glomerulus 
allowing more albumin to enter the filtrate and (ii) inability of the proximal tubules to endocytose the increased 
protein load (see ref. 9 and references therein). The development of albuminuria is a typical characteristic of renal 
damage (nephropathy ref. 31). Previous studies have demonstrated that statins can inhibit tubular reabsorption of 
filtered albumin32, 33. Furthermore, this notion is supported by a recent study in hypertensive patients demonstrat-
ing that statin treatment was independently associated with the occurrence of microalbuminuria34. Exposure to 
raised levels of albumin in the renal tubule has been linked to increased proinflammatory and profibrotic changes 
in the tubulointerstitium35.
Diabetic patients with end-stage kidney disease have a 5-year survival rate of merely 20%36. One of the major 
features of diabetic nephropathy is the presence of fibrosis. We observed increased collagen content in the HFD 
group. Notably, rosiglitazone, but not rosuvastatin treatment, prevented the increase in renal collagen deposi-
tion, suggesting a possible link between renal fibrosis and renal function. MiR-21 is the most substantial miRNA 
involved in many fibrotic diseases and its expression is enhanced after initiation of myocardial and pulmonary 
fibrosis37, 38. MiR-21 levels are also enhanced in human kidney fibrosis18, 19. Experimental support for a causa-
tive role of miR-21 is provided by miR21-silencing experiments. Silencing of miR-21 by anti-miR-21 oligonu-
cleotide treatment in a murine model of Alport nephropathy reduced glomerulosclerosis, interstitial fibrosis, 
tubular injury, and inflammation39. Similarly, silencing miR-21 in diabetic kidneys of db/db mice ameliorated 
albuminuria, inflammation and renal fibrosis40. We observed highly enhanced miR-21 levels only after rosuvas-
tatin treatment, whereas rosiglitazone prevented its expression and was comparable to the chow group. Notably, 
gene expression of pro-fibrotic genes like α-Sma and Col1α1 (results not shown) was unaffected suggesting that 
miR-21 could be an early marker of the initiating fibrosis in the kidneys.
In conclusion, our results demonstrate that rosiglitazone reduced HFD-induced insulin levels, suppressed 
the systemic inflammatory response and protected mice from the development of albuminuria. Despite its 
anti-inflammatory properties, rosuvastatin failed to improve IR and renal function. Strikingly, the beneficial 
effects of rosiglitazone were paralleled by lowered renal expression levels of miR-21; an increase of miR-21 is 
associated with microalbuminuria development, inflammation and renal fibrosis. In all, our findings suggest 
that adiponectin does not play a major role in the disease-attenuating effect of rosiglitazone and indicate that the 
option of quenching miR-21 activity merits follow-up.
Figure 6. Effects of rosuvastatin and rosiglitazone on kidney fibrosis. HuCRPtg mice were fed chow, high-fat 
diet (HFD), HFD+0.005% (w/w) rosuvastatin (HFD Rosuva) or HFD+0.018% (w/w) rosiglitazone for 42 
weeks. (a) Representative photomicrographs of kidney sections stained with Masson’s Trichrome showing renal 
collagen deposition. (b) Quantification of tubular interstitial collagen (Sirius Red staining quantified by ImageJ 
analysis). (c) Renal miR-21 expression. Data are mean ± SD. *p < 0.05, **p < 0.01.
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Materials and Methods
Animal experiments. Animal experiments were approved by an independent Committee on the Ethics of 
Animal Experiments (DEC-Zeist, The Netherlands) and were in compliance with European Community spec-
ifications regarding the use of laboratory animals. All sample materials and organs required for this study were 
obtained from TNO-Biosciences, Leiden. Minor parts of the results (in particular body weight development over 
time) were published previously, where indicated, but are presented here as well for clarity15.
HuCRPtg mice13, 14 on a C57BL/6 background were characterised by PCR and ELISA for huCRP expression. 
Mice were housed in groups under standard conditions with a 12-h light-dark cycle and had free access to water 
and food. Mice of 12 weeks of age were fed either standard lab chow (ssniff® R/M-H, ssniff Spezialdiäten, Soest, 
Germany) or chow supplemented with 0.01% (w/w) rosuvastatin (“Crestor®”, AstraZeneca, Zoetermeer, the 
Netherlands) (t = 0). After 4 weeks (t = 4) the diets were changed and mice were divided into 4 groups consisting 
of 9 mice per group. Mice that had been fed chow were randomly distributed into 3 groups. Group 1 consisted 
of control mice that remained on the standard chow diet. Group 2 was switched to a high-fat (lard) diet (HFD) 
(23.6% fat/45% kcal% fat D12451, Research Diets, New Brunswick, New Jersey) and mice in group 3 were fed 
HFD containing 0.018% (w/w) rosiglitazone (HFD+Rosi) (Avandia, GSK, London, United Kingdom). Group 4 
consisted of mice that had been fed standard chow supplemented with 0.01% (w/w) rosuvastatin (AstraZeneca), 
and were switched after 4 weeks to HFD containing 0.005% (w/w) rosuvastatin (HFD+Rosuva). The reason to 
lower the dose of rosuvastatin is the increased absorption of rosuvastatin in the context of HFD-feeding. The 
rosuvastatin and rosiglitazone doses were based on their anti-inflammatory effects observed in previous studies41, 
42. Mice on chow diet (group 1), mice on HFD without drugs (group 2) and drug-treated mice on HFD (groups 3 
and 4) remained on their respective diets until the completion of the study at 54 weeks of age (t = 42).
Body weight monitoring and blood sampling by tail incision after 4 hours of fasting was done at t = 0 and 
weeks 2, 4, 5, 11, 34, and 42. Blood samples were collected in EDTA tubes (Sarstedt AG & Co, Nümbrecht, 
Germany) and centrifuged for 10 minutes at 6000 rpm, after which plasma was collected and immediately stored 
at −80 °C until use. Spot urine and serum (after heart puncture) was collected from all animals at the time of sac-
rifice (t = 42). Mice were sacrificed by CO2 asphyxiation after a 4-hour fast, and tissues were isolated and weighed. 
Left kidneys were fixed in formalin and embedded in paraffin, and right kidneys were snap frozen in liquid N2 
and stored at −80 °C until further use.
Plasma analyses. Human CRP in plasma was quantified by established ELISA (R&D Systems, Abingdon, 
United Kingdom) at t = 0 and weeks 2, 4, 5, 11, 34, and 42. Plasma levels of E-selectin (R&D Systems), leptin 
(R&D Systems), and adiponectin (R&D systems) were quantified up to t = 42 weeks. Plasma insulin levels were 
determined by ELISA (Mercodia, Uppsala, Sweden) and plasma glucose levels were determined by enzymatic 
assay (glucose hexokinase method, Instruchemie, the Netherlands).
Renal RNA and miRNA extraction and gene expression analysis. Total RNA was extracted from 
35 µm thin cryo-sections from kidney using RNeasy Plus Mini Kit (Qiagen N.V., Venlo, the Netherlands) accord-
ing to the manufacturer’s instructions. Integrity of RNA was determined by agarose gel electrophoresis. RNA 
quantity (OD-260) and quality (OD-260/OD-280) were determined using a NanoDrop1000 UV-Vis spectropho-
tometer (NanoDrop Technologies, Rockland, DE, USA). Total RNA was reverse-transcribed using SuperScript® 
III Reverse Transcriptase (Invitrogen, Breda,the Netherlands) and random hexamer primers (Promega, Leiden, 
the Netherlands). TaqMan® Gene Expression Assays (Life Technologies, Bleiswijk, the Netherlands) were used 
to detect the expression of selected target genes. PPIA (Mm02342430_g1) was used as an endogenous con-
trol along with the following probes for CD68 (Mm00839636_g1), VCAM-1 (Mm00449197_m1), E-selectin 
(Mm00441278_m1), and Kidney Injury Molecule-1 (KIM-1, Mm00506686_m1). Real-time PCR was performed 
in duplicate and the obtained threshold cycle (Ct) values were averaged. Relative mRNA levels were calculated 
using the comparative Ct (ΔΔCt) method, expressed as fold-change relative to chow as described previously43.
For miRNA analysis, TaqMan® microRNA Reverse Transcription Kit (Life Technologies) and a specific miR-
21 (002493) TaqMan® probe was used for reverse transcription using 10 ng of total RNA. Real-time PCR was 
performed in a 7500 Fast Real-Time PCR machine using miRNA TaqMan® probes for miR-21 (002493) and the 
endogenous control sno-202 (001232). Each sample was run in duplicate and relative miRNA levels were calcu-
lated using the comparative Ct (ΔΔCt) method, expressed as fold-change relative to chow.
Histology and immunohistochemistry. For light microscopic examinations, 3 µm renal paraffin sections 
were stained with Periodic acid-Schiff (PAS). In short, paraffin sections were deparaffinised and re-hydrated 
in distilled water. Sections were placed in 0.5% periodic acid solution for 5 minutes. After rinsing in distilled 
water, sections were incubated in Schiff ’s reagent (Sigma-Aldrich, Zwijndrecht, the Netherlands) for 15 minutes, 
followed by rinsing in lukewarm water for 5 minutes. Sections were counterstained with Mayer’s haematoxy-
lin for 1 minute and washed in tap water. Images were taken with a Leica microscope using QwinV3 software 
(Qwin V3 software, Leica Microsystems Imaging Solutions Ltd., Cambridge, UK). Immunofluorescence staining 
of KIM-1 was performed using antibody NBP1-76701 (Novus Biologicals, Abingdon, UK). For direct visuali-
zation of collagen fibers in kidney, a trichrome staining was performed using the Masson’s Trichrome Staining 
kit (Accustain HT15, Sigma‐Aldrich). To quantify renal fibrosis, sections were stained with Picro-Sirius Red for 
collagen content, and the extent of fibrosis was quantified at 40x magnification using an automated macro in the 
image processing software ImageJ (version 1.48, NIH, Bethesda, MD, USA). Collagen content was expressed as 
the percentage of the total tissue area that was positively stained. Glomeruli and vessels larger than the size of 
adjacent tubules were excluded when assessing the images.
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Kidney function measured by albumin/creatinine ratio. To assess renal function, urinary albu-
min and creatinine levels were measured using commercially available kits. For this, Mouse Albumin ELISA 
Quantitation Set (Bethyl laboratories, Montgomery, Tx, USA) and The Creatinine Companion assay (Exocell, 
Philadelphia, PA, USA) were applied according to the manufacturer’s instructions.
Statistical analysis. Data were analyzed with Graphpad Prism software (version 5.03, Graphpad Software 
Inc., La Jolla, California) and SPSS (version 22, IBM, Armonk, New York). Differences between groups at one spe-
cific time point were analysed by 1-way ANOVA followed by LSD post-hoc analysis. To determine the correlation 
between two parameters, Spearman’s correlation coefficients were calculated. A p-value ≤ 0.05 was considered 
statistically significant. All data are presented as mean ± SD.
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